bibliographicCitation |
Wu Q, Qin Y, Liao W, Zhang M, Yang Y, Zhang P, Li Q. Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma. Ther Adv Med Oncol. 2022;14():17588359211068733. PMID: 35096146; PMCID: PMC8796084. |